Telo Historical Income Statement

Stocks . Canada . 
Stock . Telo Genomics Corp
TELO Stock  CAD 0.12  0.01  9.09%   
Historical analysis of Telo Genomics income statement accounts such as Interest Expense of 7.1 K, Research Development of 834.8 K, Cost Of Revenue of 55.4 K or Net Interest Income of 0.0 can show how well Telo Genomics Corp performed in making a profits. Evaluating Telo Genomics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Telo Genomics's future profits or losses.
Cash Flow   Balance Sheet     Income Statement
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Telo Genomics Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Telo Genomics Corp is a good buy for the upcoming year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telo Genomics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

About Telo Income Statement Analysis

Telo Genomics Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Telo Genomics shareholders. The income statement also shows Telo investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Telo Genomics Income Statement Chart

At this time, Telo Genomics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to climb to 7,065 in 2024, whereas Other Operating Expenses is likely to drop slightly above 2.3 M in 2024.
Selling General Administrative  Other Operating Expenses  Total Operating Expenses  Research Development  
Add Fundamental

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Telo Genomics Corp. It is also known as Telo Genomics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most accounts from Telo Genomics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Telo Genomics Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telo Genomics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
At this time, Telo Genomics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to climb to 7,065 in 2024, whereas Other Operating Expenses is likely to drop slightly above 2.3 M in 2024.
 2021 2022 2023 2024 (projected)
Cost Of Revenue57.0K33.1K38.1K55.4K
Research Development1.1M1.4M1.6M834.8K

Telo Genomics income statement Correlations

Depreciation And Amortization
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income
Income Tax Expense
Gross Profit
Net Income From Continuing Ops
Research Development
Cost Of Revenue
Reconciled Depreciation
Depreciation And Amortization
0.410.35-0.37-0.45-0.360.35-0.38-0.39-0.380.78-0.59-0.410.090.550.53
Selling General Administrative
0.410.98-0.98-0.97-0.980.98-0.99-0.88-0.990.38-0.5-0.980.550.510.04
Other Operating Expenses
0.350.98-1.0-0.98-1.01.0-1.0-0.81-1.00.29-0.52-0.980.710.54-0.09
Operating Income
-0.37-0.98-1.00.981.0-1.01.00.821.0-0.290.520.98-0.68-0.540.07
Ebit
-0.45-0.97-0.980.980.98-0.980.980.820.98-0.390.590.99-0.7-0.610.04
Ebitda
-0.36-0.98-1.01.00.98-1.01.00.811.0-0.280.520.98-0.7-0.550.09
Total Operating Expenses
0.350.981.0-1.0-0.98-1.0-1.0-0.81-1.00.29-0.52-0.980.710.54-0.09
Income Before Tax
-0.38-0.99-1.01.00.981.0-1.00.831.0-0.310.520.98-0.66-0.540.05
Total Other Income Expense Net
-0.39-0.88-0.810.820.820.81-0.810.830.83-0.420.250.84-0.26-0.24-0.33
Net Income
-0.38-0.99-1.01.00.981.0-1.01.00.83-0.310.520.98-0.66-0.540.05
Income Tax Expense
0.780.380.29-0.29-0.39-0.280.29-0.31-0.42-0.31-0.4-0.37-0.040.360.37
Gross Profit
-0.59-0.5-0.520.520.590.52-0.520.520.250.52-0.40.53-0.49-0.980.06
Net Income From Continuing Ops
-0.41-0.98-0.980.980.990.98-0.980.980.840.98-0.370.53-0.67-0.560.04
Research Development
0.090.550.71-0.68-0.7-0.70.71-0.66-0.26-0.66-0.04-0.49-0.670.54-0.49
Cost Of Revenue
0.550.510.54-0.54-0.61-0.550.54-0.54-0.24-0.540.36-0.98-0.560.54-0.17
Reconciled Depreciation
0.530.04-0.090.070.040.09-0.090.05-0.330.050.370.060.04-0.49-0.17
Click cells to compare fundamentals

Telo Genomics Account Relationship Matchups

High Positive Relationship

Total Operating Expenses
+ 1.0
Other Operating Expenses
Ebitda
+ 1.0
Operating Income
Income Before Tax
+ 1.0
Operating Income
Net Income
+ 1.0
Operating Income
Income Before Tax
+ 1.0
Ebitda
Net Income
+ 1.0
Ebitda

High Negative Relationship

Net Income
- 1.0
Total Operating Expenses
Income Before Tax
- 1.0
Total Operating Expenses
Total Operating Expenses
- 1.0
Ebitda
Total Operating Expenses
- 1.0
Operating Income
Net Income
- 1.0
Other Operating Expenses
Income Before Tax
- 1.0
Other Operating Expenses

Telo Genomics income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization64.7K62.2K57.0K33.1K29.8K54.5K
Selling General Administrative946.1K653.3K986.6K1.5M1.7M1.6M
Other Operating Expenses1.3M1.3M2.1M2.8M3.2M2.3M
Operating Income(1.2M)(1.1M)(2.1M)(2.8M)(2.5M)(2.7M)
Ebit(1.2M)(1.1M)(2.1M)(2.8M)(2.5M)(2.7M)
Ebitda(1.2M)(1.0M)(2.1M)(2.8M)(2.5M)(2.6M)
Total Operating Expenses1.3M1.3M2.1M2.8M3.2M2.3M
Income Before Tax(1.2M)(1.1M)(2.1M)(2.8M)(2.5M)(2.7M)
Total Other Income Expense Net95.7K187.2K(5.4K)(5.2K)(6.0K)(6.3K)
Net Income(1.2M)(1.1M)(2.1M)(2.8M)(2.5M)(2.7M)
Gross Profit(64.7K)(62.2K)(57.0K)(33.1K)(29.8K)(31.3K)
Net Income From Continuing Ops(1.2M)(1.1M)(2.1M)(2.8M)(3.2M)(3.4M)
Research Development364.7K603.9K1.1M1.4M1.6M834.8K
Cost Of Revenue64.7K62.2K57.0K33.1K38.1K55.4K
Net Income Applicable To Common Shares(1.1M)(1.2M)(1.1M)(2.1M)(2.4M)(2.5M)
Reconciled Depreciation64.7K62.2K57.0K33.1K29.8K28.3K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Telo Stock Analysis

When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY